伊班膦酸钠的临床研究进展

Recent advance in clinical trials of ibandronate monosodium

伊班膦酸钠属第 3代二膦酸盐类药物 ,是迄今为止本类药物中抑制骨重吸收能力最强、毒性最低的药物。本文综述了伊班膦酸钠用于治疗癌症骨转移或肿瘤引发的高钙血症的临床资料以及伊班膦酸钠的临床药动学资料 ,并对该药的临床安全性进行了评价。此外 ,国外正在进行伊班膦酸钠治疗绝经后骨质疏松症和变形性骨炎的临床试验 。

Ibandronate is a newly developed third generation bisphosphonate with the highest potency, relative to other members of its class, in inhibiting bone resorption, and with much higher advantage with regard to the tolerability in clinical study. The authors reviewed the treatment with ibandronate of cancer bone-transffer or tumor-induced hypercalcaemia, and the clinical pharmacokinetic profiles and tolerability of ibandronate. The clinical safety of the drug has been evaluated too. Ibandronate has also been used with great success in late phase clinical trials for the treatment of postmenopausal women with osteoporosis, and for the treatment of Paget's disease.